The 2022 position statement confirms hormone therapy as the most effective treatment for vasomotor symptoms in menopause and includes updated guidelines for age- and condition-specific treatment plans.
The North American Menopause Society (NAMS) published its 2022 hormone therapy position statement in Menopause on July 7, 2022.1 The new guidelines considered and incorporated the most recent research and literature published since the previous statement in 2017.2
“Since our last Position Statement,” said Stephanie S. Faubion, NAMS medical director and lead of the Position Statement Advisory Council, “there have been important additions that further clarify the balance of risks and benefits of hormone therapy options for menopause symptoms.” What hasn’t changed, according Faubion, is hormone therapy’s effectiveness as treatment for vasomotor symptoms (VMS) and genitourinary syndrome of menopause (GSM), as well as its use for bone loss and fracture prevention.
The 2022 recommendations reiterate the importance of shared decision-making and patient education when addressing treatment options, stating that—for most healthy, symptomatic women under the age of 60 who are within 10 years of menopause onset—the benefits of hormone therapy outweigh the risks.
The statement also reported on observational data that suggested low-dose estrogen therapy to be safe for GSM treatment in women with breast and endometrial cancer who failed nonhormone therapy, and beneficial for addressing quality-of-life issues.
While randomized, controlled trial data about the risks involved with extended duration of hormone therapy are scarce, some observational studies suggested a potential—but rare—risk of breast cancer.
The statement also outlined several safety concerns with compounded bioidentical hormone therapy: